___

• 1. Erişkin Bağışıklama Rehberi Çalışma Grubu. Erişkin Bağışıklama Rehberi. Ed. Türkiye Enfeksiyon Hastalıkları ve Klinik mikrobiyoloji Derneği. Gümat matbaacılık, İstanbul Mayıs 2016: s.28- 30. 2. Centers For Disease control and Prevention (CDC). Pneumococcal Vaccination: Information for Health Care Providers. http://www.cdc.gov/vaccines/vpd-vac/pneumo/hcp/index.html 19.09.2016 tarihinde erişildi. 3. Hacımustafaoğlu M. Pnömokok Aşıları. Aşı Kitabı. Editörler Badur S, Bakır M. 1. Baskı. 2012 Akademi Uluslarası Yayıncılık sanayi ve tic. Ltd Şti.; İstanbul. s:253-270. 4. Centers For Disease control and Prevention (CDC). PneumococcalDisease. http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo. html 19.09.2016 tarihinde erişildi. 5. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcaldisease among children under five: the pneumococcal global serotype project. PLoS Medicine, 2010, 7: pii: e1000348. 6. Ulusal Antimikrobiyal Direnç Surveyans Sistemi, 2013 Yılı Yıllık Raporu, Türkiye Halk Sağlığı Kurumu, Sağlık Bakanlığı Ankara, http://uamdss.thsk.gov.tr 19.09.2016 tarihinde erişildi. 7. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines. Thorax. 2001;56:296–301. doi: 10.1136/thorax. 56.4.296. 8. Woodhead M. Community-acquired pneumonia in Europe: Causative pathogens and resistance patterns.Eur. Respir. J. Suppl. 2002;36:20s–27s. doi: 10.1183/09031936.02.00702002. 9. T.C. Sağlık Bakanlığı Refik Saydam Hıfzıssıhha Merkezi Başkanlığı Hıfzıssıhha Mektebi Müdürlüğü, Başkent Üniversitesi . Ulusal hastalık yükü ve maliyet-etkililik projesi. Aralık 2004. Hastalık yükü final rapor . Aralık 2004. s:43 http://ekutuphane.tusak.gov.tr/kitaplar/turkiye_hastalik_yuku_calismasi. pdf 24.09.2016 tarihinde ulaşıldı 10 Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, et al. Seasonality of invasive pneumococcal disease: temporal relation to documentedinfluenza and respiratory syncytial viral circulation. American Journal of Medicine, 2005, 118:285-291. 11. Guillamet CV, Vazquez R, Noe J, Micek ST, Kollef MH.A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy? Medicine (Baltimore). 2016 Aug;95(35):e4708. doi: 10.1097/MD.0000000000004708. 12. World Health Organisation. Pneumococcal vaccines WHO positionpaper- 2012. http://www.who.int/wer/2012/wer8714.pdf?ua=1 20.09.2016 da erişildi 13. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Reviewand Meta-Analysis. PLoS One. 2016 Jan 13;11(1):e0146338. doi: 10.1371/journal. pone.0146338. eCollection 2016. 14. Pichichero ME. Protein carriers of conjugate vaccines. Characteristics, development, and clinical trials Hum Vaccin Im munother. 2013 Dec 1; 9(12): 2505–2523.doi: 10.4161/hv.26109 15. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pnemococcal conjugate vaccine in USA: a time series analysis. Lancet 2007;369:1179 16. Fireman B, Black SB, Shinefield Hr, Lee J, Lewis E, Ray P. Impact of pneumococcal conjugate vaccine on otitis media. Pediatr Infec Dis J 2003, 22:10 17. Madhi SA, Klugman KP, Vaccine Trialist group. A role for streptococcus pneumonia in virüs associated pnemonia. Nat Med 2004;10:811 18. de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008;46:1015–23 19. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C,et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013;31:3577-3584 20. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 2015;372:1114–1125. doi: 10.1056/NEJMoa1408544. CAPITA 21. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013;31:3585-3593 22. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. Vaccine 2014;32:2364–74. 23. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594–602 24. Ishiguro T, Kagiyama N, Uozumi R, Odashima K, Kurashima K, Morita S, et al. Risk factors for the severity and mortality of pneumococcal pneumonia: Importance of premorbid patients' performance status. J Infect Chemother. 2016 Oct;22(10):685-91. doi: 10.1016/j.jiac.2016.07.008. 25. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Reviewand Meta-Analysis. PLoS One. 2016 Jan 13;11(1):e0146338. doi: 10.1371/journal. pone.0146338. eCollection 2016. 26. La Torre G, Mannocci A, Colamesta V, D'Egidio V, Sestili C, Spadea A. Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety. Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016044. doi: 10.4084/MJHID.2016.044. eCollection 2016. 27. Marrie TJ, Tyrrell GJ, Majumdar SR, Eurich DT.Asplenic patients and invasive pneumococcal disease-how bad is it these days? Int J Infect Dis. 2016 Aug 30;51:27-30. doi: 10.1016/j.ijid.2016.08.022. [Epub ahead of print] 28. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of PCV-13 and PPSV-23 vaccine among adults aged 65 and older: recommendations of the ACIP(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.ht m). MMWR. 2014;63(37);822-5. 29. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, MD, Whitney CG et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015;64:944–7.